Preclinical activity profile and therapeutic efficacy of the hsp90 inhibitor ganetespib in triple-negative breast cancer

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 413-424

  Proia, David A ^a   Zhang, Chaohua ^a   Sequeira, Manuel ^a   Jimenez, John Paul ^a   He, Suqin ^a   Spector, Neil ^d   Shapiro, Geoffrey I ^b   Tolaney, Sara ^c   Nagai, Masazumi ^a   Acquaviva, Jaime ^a   Smith, Donald L ^a   Sang, Jim ^a   Bates, Richard C ^a   El Hariry, Iman ^a  

^a Synta Pharmaceuticals Corp   (United States)

^b Early Drug Development Center   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; PACLITAXEL; TAXANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE REGULATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; MITOSIS INHIBITION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MICE; MITOSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892764962     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2166     Document Type: Article

References (50)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, JeffreySS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-74.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
6. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triplenegative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-27.
7. Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20.
8. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011;16 Suppl 1:1-11.
9. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12 Suppl 2:S3.
10. Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 2009;63:269-74.
11. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: A complex and deadly molecular subtype. Current Mol Med 2012;12:96-110.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
13. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010;11:515-28.
14. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
15. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
16. Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012;65:471-517.
17. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17:5132-9.
18. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475-84.
19. Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs 2012;30: 2201-9.
20. Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, et al. Targeting KRAS mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012;11:2633-43.
21. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012;18:4973-85.
22. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 2013;42:35-43.
23. Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA- 9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE 2011;6:e18552.
24. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013;19:3068-77.
25. Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, et al. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs 2013 May 18; [Epub ahead of print].
26. Dirks WG, Drexler HG. Online verification of human cell line identity by STR DNA typing. Methods Mol Biol 2011;731:45-55.
27. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology andutility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-21.
28. Miretti S, Roato I, Taulli R, Ponzetto C, Cilli M, Olivero M, et al. A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. PLoS ONE 2008;3:e1828.
29. Elkin M, Vlodavsky I. Tail vein assay of cancer metastasis. In:Bonifacino JS, et al., editors. Current protocols in cell biology. New York: John Wiley & Sons; 2001;12:19.2.1-19.2.7.
30. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. In: Coligan JE, et al., editors. Current protocols in immunology. New York: John Wiley & Sons; 2001;39:20.2.1-20.2.16.
31. Kaplan KB, Li R. A prescription for 'stress' - the role of Hsp90 in genome stability and cellular adaptation. Trends Cell Biol 2012;22: 576-83.
32. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61.
33. Imreh G, Norberg HV, Imreh S, Zhivotovsky B. Chromosomal breaks during mitotic catastrophe trigger gammaH2AX-ATM-p53-mediated apoptosis. J Cell Sci 2011;124:2951-63.
34. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009;106:8368-73.
35. Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res 2011;17:5432-42.
36. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90.
37. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65: 4929-38.
38. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008;7:1985-92.
39. Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, Nalabothula NR, et al. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther 2011;10:1194-206.
40. Barker CR, McNamara AV, Rackstraw SA, Nelson DE, White MR, Watson AJ, et al. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res 2006;34:1148-57.
41. Jenkins Jr. A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons). Br J Radiol 2008;81:S69-77.
42. Nguyen DM, Lorang D, Chen GA, Stewart JH IV, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371-8.
43. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy- induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
44. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, et al. Potentiation of paclitaxel activity by the HSP90 inhibitor 17- allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006;5:1197-208.
45. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizesEGFR mutant tumors to paclitaxel. Cancer Res 2008;68:589-96.
46. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
47. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005;4:1495-504.
48. Ramalingam S, Goss GD, Andric ZG, Bondarenko I, Zaric B, Ceric T, et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenomacarcinoma (GALAXY-1). J Clin Oncol 2013;31(suppl):CRA8007 [abstract].
49. Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol 2012;23:vi40-5.
50. Laporte S, Jones S, Chaelle C, Jacquin J, Martin M. Consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials. Cancer Res 2009;69:24.